15-Year experience on intravesical therapy of T1G3 urinary bladder cancer: A conservative approach

Japanese Journal of Clinical Oncology

Volumn 34, Issue 4, 2004, Pages 202-205

  Cheng, Chi Wai ^a   Chan, Siu Foon Peter ^a   Chan, Lung Wai ^a   Chan, Chi Kwok ^a   Ng, Chi Fai ^a   Cheung, Ho Yuen ^a   Chan, Shu Yin Eddie ^a   Wong, Wai Sang ^a   Lai, Fernand Mac Moune ^a   Li, Miu Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BCG vaccine; Bladder neoplasms; Doxorubicin; Epirubicin; Transitional cell

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ANTINEOPLASTIC ANTIBIOTIC; BCG CONNAUGHT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRANSURETHRAL RESECTION; BLADDER TUMOR; DISEASE COURSE; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 18344405440     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh030     Document Type: Article

References (20)

1. Herr HW, Jakse G, Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8:254-61.
2. Stockle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy - often too late? Eur Urol 1987;13:361-7.
3. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical eystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-5.
4. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9.
5. Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996;155:1907-9.
6. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, et al. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: Long-term results. J Urol 1995;154: 2054-9.
7. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997;80:762-5.
8. Hurle R, Losa A, Manzetti A, Lembo A. Intravesical bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: A 7-year follow-up. Urology 1999;54:258-63.
9. Baniel J, Grauss D, Engelstein D, Sella A. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998;52:785-9.
10. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1987;137:220-4.
11. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404-8.
12. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156: 1934-40.
13. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-9.
14. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476-81.
15. Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B. Intravesical bacillus Calmette-Guérin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2001;41:635-41.
16. Kulkarni JN, Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain). BJU Int 2002;90:554-7.
17. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J Urol 2003;169:96-100.
18. Hara I, Miyake H, Takechi Y, Eto H, Gotoh A, Fujisawa M, et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int J Urol 2003;10:19-24.
19. Peyromaure M, Guérin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M. Intravesical bacillus Calmette-Guérin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: Recurrence, progression and survival in a study of 57 patients. J Urol 2003;169:2110-2.
20. Bono AV, Lovisolo, JA, Saredi G. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 2000;37:478-83.